UBS Group Issues Positive Forecast for PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price

Posted by Geri Gentry on Nov 5th, 2026

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) had its target price boosted by stock analysts at UBS Group from $20.00 to $21.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group‘s price objective would indicate a potential upside of 3.60% from the company’s current price.

PRCT has been the topic of several other research reports. Evercore set a $23.00 price objective on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Jefferies Financial Group reaffirmed a “hold” rating and set a $20.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Wells Fargo & Company downgraded shares of PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, October 15th. Finally, Barclays initiated coverage on shares of PROCEPT BioRobotics in a research note on Tuesday, October 6th. They set an “overweight” rating and a $30.00 target price for the company. Three research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $25.00.

Check Out Our Latest Research Report on PROCEPT BioRobotics

PROCEPT BioRobotics Stock Down 6.4%

Shares of NASDAQ:PRCT traded down $1.39 during midday trading on Thursday, reaching $20.27. The company had a trading volume of 3,108,199 shares, compared to its average volume of 1,509,829. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $38.11. The stock has a market cap of $1.16 billion, a PE ratio of -10.45 and a beta of 0.88. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average price is $19.34 and its 200 day moving average price is $23.23.

PROCEPT BioRobotics (NASDAQ:PRCT – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.07). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $98.29 million during the quarter, compared to analyst estimates of $100.52 million. During the same period in the previous year, the company posted ($0.38) EPS. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. Research analysts forecast that PROCEPT BioRobotics will post -1.67 EPS for the current fiscal year.

Insider Activity

In related news, CEO Larry Wood purchased 23,900 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders sold 1,043 shares of company stock worth $21,851. Corporate insiders own 4.00% of the company’s stock.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of large investors have recently modified their holdings of PRCT. BlackRock Inc. bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter valued at approximately $109,961,000. Jupiter Topco LLC bought a new position in PROCEPT BioRobotics during the 2nd quarter worth approximately $24,914,000. William Blair Investment Management LLC acquired a new position in PROCEPT BioRobotics in the second quarter valued at $16,020,000. Bank of America Corp DE acquired a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth approximately $11,656,000. Finally, CPMG Inc acquired a new stake in shares of PROCEPT BioRobotics in the 1st quarter valued at about $10,661,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

Positive Sentiment: Revenue rose 18% year over year, and PROCEPT reaffirmed its 2026 financial guidance, providing a positive counterpoint to the quarterly earnings miss. Company results and guidance
Neutral Sentiment: Leerink Partners raised its price target from $20 to $22 but kept a Market Perform rating, signaling limited near-term conviction despite the higher target. Leerink Partners ratings
Negative Sentiment: PRCT reported a quarterly loss of $0.46 per share, wider than the $0.39 loss analysts expected and the $0.38 loss a year earlier. Revenue of $98.3 million also fell short of the roughly $100.5 million consensus. The earnings and sales misses likely weighed on the shares. Q3 results and estimates

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.